HN1999000105A - Compuestos de 1-piperidil benzoimidazol 2-sustituidos como agonistas de receptores orli. - Google Patents

Compuestos de 1-piperidil benzoimidazol 2-sustituidos como agonistas de receptores orli.

Info

Publication number
HN1999000105A
HN1999000105A HN1999000105A HN1999000105A HN1999000105A HN 1999000105 A HN1999000105 A HN 1999000105A HN 1999000105 A HN1999000105 A HN 1999000105A HN 1999000105 A HN1999000105 A HN 1999000105A HN 1999000105 A HN1999000105 A HN 1999000105A
Authority
HN
Honduras
Prior art keywords
compounds
substituted
piperidil
benzoimidazole
receptor agonists
Prior art date
Application number
HN1999000105A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN1999000105A publication Critical patent/HN1999000105A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS DE PIPERIDIN-4-11 1-SUSTITUIDOBENZOIMIDAZOL 2-SUSTITUIDOS Y A SUS SALES, A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, A SUS USOS MEDICOS, A PROCEDIMIENTOS PARA PREPARAR ESTOS COMPUESTOS Y A COMPUESTOS INTERMEDIOS UTILES EN LOS PROCEDIMIENTOS.
HN1999000105A 1998-08-06 1999-07-05 Compuestos de 1-piperidil benzoimidazol 2-sustituidos como agonistas de receptores orli. HN1999000105A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06

Publications (1)

Publication Number Publication Date
HN1999000105A true HN1999000105A (es) 2000-11-11

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1999000105A HN1999000105A (es) 1998-08-06 1999-07-05 Compuestos de 1-piperidil benzoimidazol 2-sustituidos como agonistas de receptores orli.

Country Status (44)

Country Link
US (1) US6172067B1 (es)
EP (1) EP1102762B1 (es)
JP (1) JP3367945B2 (es)
CN (1) CN1317968A (es)
AP (1) AP2001002063A0 (es)
AR (1) AR018686A1 (es)
AT (1) ATE227716T1 (es)
AU (1) AU749166B2 (es)
BG (1) BG105301A (es)
BR (1) BR9912778A (es)
CA (1) CA2339621C (es)
CZ (1) CZ2001397A3 (es)
DE (1) DE69903953T2 (es)
DK (1) DK1102762T3 (es)
EA (1) EA200100104A1 (es)
EE (1) EE200100075A (es)
ES (1) ES2185357T3 (es)
GE (1) GEP20033000B (es)
GT (1) GT199900125A (es)
HK (1) HK1040188A1 (es)
HN (1) HN1999000105A (es)
HR (1) HRP20010089B1 (es)
HU (1) HUP0103567A3 (es)
ID (1) ID27212A (es)
IL (1) IL141029A0 (es)
IS (1) IS5812A (es)
MA (1) MA26659A1 (es)
NO (1) NO20010603L (es)
NZ (1) NZ509299A (es)
OA (1) OA11590A (es)
PA (1) PA8477701A1 (es)
PE (1) PE20000868A1 (es)
PL (1) PL346211A1 (es)
PT (1) PT1102762E (es)
SI (1) SI1102762T1 (es)
SK (1) SK1602001A3 (es)
SV (1) SV1999000099A (es)
TN (1) TNSN99142A1 (es)
TR (1) TR200100403T2 (es)
TW (1) TW513424B (es)
UY (1) UY25659A1 (es)
WO (1) WO2000008013A2 (es)
YU (1) YU8201A (es)
ZA (1) ZA200100900B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
ES2249237T3 (es) * 2000-01-05 2006-04-01 Pfizer Inc. Compuestos de bencimidazol como antagonistas del receptor orl1.
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
EP1342717A4 (en) * 2000-11-15 2005-02-16 Banyu Pharma Co Ltd benzimidazole derivatives
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
DE60229736D1 (de) 2001-04-18 2008-12-18 Euro Celtique Sa Spiroinden- und spiroindan-verbindungen
AU2002307416B2 (en) * 2001-04-18 2005-08-11 Euro-Celtique S.A. Nociceptin analogs
BR0209127A (pt) 2001-04-18 2006-03-21 Euro Celtique Sa compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
HUP0402510A3 (en) 2001-04-18 2012-08-28 Euro Celtique Sa Nociceptin analogs and pharmaceutical compositions containing them
US6872733B2 (en) * 2001-04-18 2005-03-29 Euro-Celtique S.A. Benzimidazolone compounds
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
WO2003082333A1 (fr) 2002-03-29 2003-10-09 Mitsubishi Pharma Corporation Remede contre les troubles du sommeil
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
AR045939A1 (es) 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
WO2006038738A1 (ja) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2006074991A1 (en) 2005-01-11 2006-07-20 Neurosearch A/S Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
AU2007271243A1 (en) * 2006-07-03 2008-01-10 Neurosearch A/S Combinations of monoamine reuptake inhibitors and potassium channel activators
PT2076506E (pt) 2007-01-16 2010-12-10 Purdue Pharma Lp Compostos de piperidina substituídos nos grupos heterocíclicos como ligandos orl-1
ES2593706T3 (es) * 2007-08-31 2016-12-12 Purdue Pharma Lp Compuestos de piperidina, de tipo quinoxalina sustituida, y usos de los mismos
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
AR072578A1 (es) 2008-07-21 2010-09-08 Purdue Pharma Lp Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos
SG187209A1 (en) 2010-08-05 2013-03-28 Amgen Inc Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
WO2013103598A2 (en) 2012-01-06 2013-07-11 Novus International Inc. Sulfoxide-based surfactants
RS57845B1 (sr) 2012-02-09 2018-12-31 Novus Int Inc Ciklični dimeri koji sadrže heteroatom
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
CN107753462B (zh) 2012-07-12 2021-01-08 诺华丝国际股份有限公司 用于保护生物活性剂的基质和层组合物
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9656994B2 (en) 2013-03-22 2017-05-23 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
PT3119762T (pt) * 2014-03-20 2021-08-31 Capella Therapeutics Inc Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
US10227551B2 (en) 2015-11-12 2019-03-12 Novus International, Inc. Sulfur-containing compounds as solvents
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
JP4191796B2 (ja) 1995-08-15 2008-12-03 ユーロスクリーン・ソシエテ・アノニム 拮抗剤または作動剤として、ヒトorl1受容体に結合できることが知られていない化合物を回収する方法
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
AU2388697A (en) * 1996-04-19 1997-11-12 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP0813065A3 (en) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
EP0829481A1 (en) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
ATE276242T1 (de) 1997-05-30 2004-10-15 Banyu Pharma Co Ltd 2-oxoimidazol-derivate
AU8334298A (en) 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
AU4385999A (en) 2000-02-28
JP3367945B2 (ja) 2003-01-20
SK1602001A3 (en) 2002-09-10
JP2002522431A (ja) 2002-07-23
DK1102762T3 (da) 2002-12-16
US6172067B1 (en) 2001-01-09
NO20010603L (no) 2001-04-05
DE69903953T2 (de) 2003-03-27
ZA200100900B (en) 2002-08-28
CA2339621C (en) 2005-04-05
EP1102762A2 (en) 2001-05-30
MA26659A1 (fr) 2004-12-20
AU749166B2 (en) 2002-06-20
PE20000868A1 (es) 2000-08-31
EE200100075A (et) 2002-06-17
UY25659A1 (es) 2000-02-23
PA8477701A1 (es) 2000-09-29
YU8201A (sh) 2003-07-07
GEP20033000B (en) 2003-06-25
ATE227716T1 (de) 2002-11-15
EP1102762B1 (en) 2002-11-13
NO20010603D0 (no) 2001-02-05
BR9912778A (pt) 2001-09-25
GT199900125A (es) 2001-01-27
HUP0103567A2 (hu) 2002-02-28
HUP0103567A3 (en) 2003-01-28
SI1102762T1 (en) 2003-04-30
AP2001002063A0 (en) 2001-03-31
ID27212A (id) 2001-03-08
CZ2001397A3 (cs) 2002-05-15
TW513424B (en) 2002-12-11
EA200100104A1 (ru) 2001-08-27
PT1102762E (pt) 2003-02-28
HK1040188A1 (zh) 2002-05-31
HRP20010089A2 (en) 2002-02-28
DE69903953D1 (de) 2002-12-19
NZ509299A (en) 2003-05-30
SV1999000099A (es) 2000-09-05
HRP20010089B1 (en) 2003-04-30
ES2185357T3 (es) 2003-04-16
PL346211A1 (en) 2002-01-28
WO2000008013A3 (en) 2000-03-23
AR018686A1 (es) 2001-11-28
OA11590A (en) 2004-08-18
IL141029A0 (en) 2002-02-10
CA2339621A1 (en) 2000-02-17
CN1317968A (zh) 2001-10-17
IS5812A (is) 2001-01-16
TNSN99142A1 (fr) 2005-11-10
WO2000008013A2 (en) 2000-02-17
BG105301A (en) 2001-12-29
TR200100403T2 (tr) 2001-07-23

Similar Documents

Publication Publication Date Title
HN1999000105A (es) Compuestos de 1-piperidil benzoimidazol 2-sustituidos como agonistas de receptores orli.
GT199900008A (es) Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1
UY30709A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-dioxido sustituidos con radicales bencilo, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
HN2003000408A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
PA8576101A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
GT199900215A (es) Formulaciones agroquimicas.
HN2001000224A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
PA8592201A1 (es) Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
UY31525A1 (es) Derivados de aminobenzamida con agentes utiles para controlar parasitos animales
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
HN1999000106A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
ES2054860T3 (es) Nuevos derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion, asi como a su utilizacion como medicamentos.
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
CR7168A (es) Ligandos del receptor de 5.ht y sus usos
PA8528501A1 (es) Derivados de purina
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
PA8452701A1 (es) Agonistas de prostaglandinas
SV2004001549A (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
CU23415B7 (es) Derivados de 2,6- quinolinilo y 2,6- naftilo, procesos para su preparación y sus usos
CR8178A (es) Sistemas de emulsion que contienen derivados de azetidina
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
HN2000000045A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.
SV1999000115A (es) Derivados de sulfonamida ref. x-12301